Receptor targeting drug delivery strategies and prospects in the treatment of rheumatoid arthritis

Emami, Jaber; Ansarypour, Zahra

doi:10.4103/1735-5362.272534

Cited by 16 publications

(8 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was an apparent direct correlation between T cell CD4 naïve and B cell memory. Theoretically, antigen-presenting cells in RA joints may stimulate synovial CD4 + T cells to differentiate into T helper cells, which in turn activate B cells, some of which are differentiated into plasma cells that produce autoantibodies [ 81 ]. The immunocyte correlation analysis shows that most of the immune cells in RA have different degrees of correlation, suggesting that various immune cells may interact to form a highly complex immunosuppressive network.…”

Section: Discussionmentioning

confidence: 99%

Identification of potential ferroptosis key genes and immune infiltration in rheumatoid arthritis by integrated bioinformatics analysis

Fan,

Li,

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Identification of potential ferroptosis key genes and immune infiltration in rheumatoid arthritis by integrated bioinformatics analysis

Fan,

Li,

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…Furthermore, the distribution and retention of nanoparticles within joints is favored by an initial stage of RA in which the synovial membrane increases the number of cell layers, leading to hypoxia and angiogenesis. As the developed vasculature leaks into the joints, this outcome allows the accumulation of NLCs in the affected zone [38][39][40]A PDI value close to 0.2 means that the size distribution of NLCs is narrow, improving their performance. Finally, a ZP value close to ± 30 mV reflects better stability of NLCs, due to the repulsion between particles that minimize the formation of aggregates [41,42] .…”

Section: -Nlc-tfmmentioning

confidence: 99%

Development and Optimization of Teriflunomide-Loaded Chondroitin Sulphate-Coated Nanostructured Lipid Carriers (Nlcs) Through Box Behnken Design

Campos,

Torres-Vergara,

Godoy

et al. 2023

J. Chil. Chem. Soc.

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an autoimmune chronic disease characterized by disabling pain and deformity of the joints. Teriflunomide (TFM), a metabolite from leflunomide, is given orally to RA patients, but its gastrointestinal and systemic side effects are severe and not well tolerated. This study aims to optimize and develop nanostructured lipid carriers (NLC) loaded with teriflunomide (NLC-TFM). NLCs were developed by homogenization and ultrasound. The optimization parameters were achieved through a Box-Behnken experimental design. The optimized NLC-TFM were also coated with chondroitin sulfate (NLC-TFM-CHS) to enhance its interaction with target tissues and shift its focus to intra-articular administration. Both formulations were characterized in their morphology, particle size (PS), Zeta potential, entrapment efficiency (EE%), drug loading (DL%), molecular interactions and in vitro release kinetics. The developed NLC-TFM and NLC-TFM-CHS exhibited a spherical morphology, Zeta potential lower than -30 mV, mean PS of 178.6-211 nm, EE% of 85.95-65.78 % and DL% of 3.97-2.97%, respectively. Thermal and crystalline behavior analyses suggested that TFM is dissolved within the lipidic matrix. The release of TFM showed a biphasic pattern, with an initial burst release followed by a sustained release, being the latter more marked in NLC-TFM-CHS. The developed formulations show promise as delivery systems for targeted therapy of RA through intra-articular administration.

show abstract

“…Yet, surgeries also carry a prevalent risk of bleeding, infection, and pain, in addition to being costly and time-consuming. Overall, various drugs are not safe and effective for treating RA (10). Thus, a drug targeted for a particular gene and network may have a significant effect on the current patient and in stopping the genetic transmissions of disease-causing agents in Rheumatoid Arthritis.…”

Section: Introductionmentioning

confidence: 99%

“…Thus, a drug targeted for a particular gene and network may have a significant effect on the current patient and in stopping the genetic transmissions of disease-causing agents in Rheumatoid Arthritis. Notably, the inflamed synovial tissue has been found to have great potential for passive and active drug targeting due to its enhanced permeability and retention effect (10). This tissue also consists of numerous RA synovial macrophages and fibroblasts that express surface receptors.…”

Section: Introductionmentioning

confidence: 99%

A Computational Modeling Framework to Analyze Synovial-Tissue Based Drug Targets and Diagnostic Biomarkers in Rheumatoid Arthritis

Latawa¹,

Chrisman

2021

Preprint

View full text Add to dashboard Cite

Rheumatoid Arthritis (RA) is an inflammatory autoimmune disease that affects 23 million people worldwide. It is a clinically heterogeneous disorder characterized by the attack of inflammatory chemicals on the synovial tissue that lines joints. It is advantageous to develop effective, targeted treatments and identify specific diagnostic biomarkers for RA before extensive joint degradation, bone erosion, and cartilage destruction. Current modes of RA treatments have alleviated and notably halted the progression of RA. Despite this, not many patients reach low disease activity status after treatment, and a significant number of patients fail to respond to medication due to drug non-specificity. While the reasons for these rates remain unknown, the cellular and molecular signatures present in the synovial tissue for RA patients likely play a role in the varied treatment response. Thus, a drug that particularly targets specific genes and networks may have a significant effect in halting the progression of RA. This study evaluates and proposes potential drug targets through in silico mathematical modeling of various pathways of interest in RA. To understand how drugs interact with genes, we built a mathematical model with 30 two-gene and three-gene network interactions and analyzed the effect of 92 different perturbations to rate constants. We determined that inhibition of the LCK-CD4, VAV1-CD4, and MLT-ROR pathways could potentially serve as drug targets. We also found that increased activity of the DEC2-IL1β and the NF-kB-interleukin pathway and the decreased activity of the TNF-α-REV-ERB pathway could serve as diagnostic biomarkers.

show abstract

Receptor targeting drug delivery strategies and prospects in the treatment of rheumatoid arthritis

Cited by 16 publications

References 115 publications

Identification of potential ferroptosis key genes and immune infiltration in rheumatoid arthritis by integrated bioinformatics analysis

Identification of potential ferroptosis key genes and immune infiltration in rheumatoid arthritis by integrated bioinformatics analysis

Development and Optimization of Teriflunomide-Loaded Chondroitin Sulphate-Coated Nanostructured Lipid Carriers (Nlcs) Through Box Behnken Design

A Computational Modeling Framework to Analyze Synovial-Tissue Based Drug Targets and Diagnostic Biomarkers in Rheumatoid Arthritis

Contact Info

Product

Resources

About